Literature


  1. Lee CK, Brown C, Gralla RJ, et al. (2013) Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst 105:595–605. doi: 10.1093/jnci/djt072
  2. Shaw AT, Kim D-W, Nakagawa K, et al. (2013) Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer. N Engl J Med 368:130601060020006. doi: 10.1056/NEJMoa1214886
  3. Sadiq A a, Salgia R (2013) MET as a possible target for non-small-cell lung cancer. J Clin Oncol 31:1089–96. doi: 10.1200/JCO.2012.43.9422
  4. Bergethon K, Shaw AT, Ou S-HI, et al. (2012) ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30:863–70. doi: 10.1200/JCO.2011.35.6345
  5. Marchetti A, Felicioni L, Malatesta S, et al. (2011) Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol 29:3574–9. doi: 10.1200/JCO.2011.35.9638
  6. Oxnard GR, Binder A, Jänne P a (2013) New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol 31:1097–104. doi: 10.1200/JCO.2012.42.9829
  7. Mazières J, Peters S, Lepage B, et al. (2013) Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 31:1997–2003. doi: 10.1200/JCO.2012.45.6095
  8. Pirker R, Pereira JR, von Pawel J, et al. (2012) EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 13:33–42. doi: 10.1016/S1470-2045(11)70318-7
  9. Reungwetwattana T, Molina JR, Mandrekar SJ, et al. (2012) Brief report: a phase II “window-of-opportunity” frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study. J Thorac Oncol 7:919–22. doi: 10.1097/JTO.0b013e31824de0d6
  10. Ohashi K, Sequist L V, Arcila ME, et al. (2013) Characteristics of lung cancers harboring NRAS mutations. Clin Cancer Res 19:2584–91. doi: 10.1158/1078-0432.CCR-12-3173
  11. Martin P, Leighl NB, Tsao M-S, Shepherd FA (2013) KRAS mutations as prognostic and predictive markers in non-small cell lung cancer. J Thorac Oncol 8:530–42. doi: 10.1097/JTO.0b013e318283d958
  12. Vaishnavi A, Capelletti M, Le AT, et al. (2013) Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med. doi: 10.1038/nm.3352
  13. Hammerman PS, Sos ML, Ramos AH, et al. (2011) Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 1:78–89. doi: 10.1158/2159-8274.CD-11-0005
  14. Ren M, Hong M, Liu G, et al. (2013) Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1. Oncol Rep 29:2181–90. doi: 10.3892/or.2013.2386
  15. Sukhai, 2015, A classification system for clinical relevance of somatic variants identified in molecular profiling of cancer. Genet Med. doi: 10.1038/gim.2015.47.
  16. David E. Gerber (2008) Targeted Therapies: A New Generation of Cancer Treatments. 1;77(3):311-319.